Published by Josh White on 17th September 2025
(Sharecast News) - Fusion Antibodies reported further validation of its OptiMAL discovery platform on Wednesday, saying its collaboration with the US National Cancer Institute had confirmed antibody binders to three cancer targets and that the NCI had asked to extend its use of the technology beyond the current agreement, which runs to November 2025.